Positive clinical trial data in 2022 could lead to record drug launches over the coming year.
Our latest thinking on the themes shaping today’s investment landscape. Explore timely updates, quarterly features and in-depth analysis straight from our experts.
Andy Acker discusses how pricing power, growing demand, and an improving outlook for biotech could bolster the sector heading into 2023.
Why health care could be well positioned to offer both defense against market volatility and opportunities for long-term growth.
Why we believe the biopharma industry should be able to adapt to drug pricing changes.
The biopharmaceutical industry often moves to the beat of its own drummer, creating opportunities for diversification.
Healthcare technology companies are providing solutions to the rising demand for healthcare, but what are the implications for investors?
What are the opportunities in the healthcare sector in today’s uncertain financial markets?
For more than a year, biotechnology stocks have been deep in the red, even as medical breakthroughs continue – a disconnect we think is unlikely to last.
Why the beaten-down biotechnology sector may be worth another look.